Kobayashi, Haruki http://orcid.org/0000-0002-3386-8063
Wakuda, Kazushige
Naito, Tateaki
Mamesaya, Nobuaki
Omori, Shota
Ono, Akira
Kenmotsu, Hirotsugu
Murakami, Haruyasu
Endo, Masahiro
Harada, Hideyuki
Gon, Yasuhiro
Takahashi, Toshiaki
Article History
Received: 9 August 2020
Accepted: 10 March 2021
First Online: 17 March 2021
Declarations
:
: The study protocol was approved by the institutional review board of the Shizuoka Cancer Center (Institutional Review Board No. J2019-29-2019-1-3).
: Not applicable.
: HK reports grants and personal fees from AstraZeneca K.K., grants and personal fees from Chugai Pharmaceutical Co, Ltd., personal fees from Ono Pharmaceutical Co, Ltd., grants and personal fees from Boehringer Ingelheim, personal fees from Eli Lilly K.K, personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Novartis Pharma K.K., grants from Daiichi Sankyo Co., Ltd., and personal fees from Taiho Pharmaceutical outside the submitted work. KW reports personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Boeringer Ingelheim, personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Taiho Pharma, and personal fees from AstraZeneca K.K. outside the submitted work. TN has nothing to disclose. NM reports grants from Boeringer Ingelheim, personal fees from MSD, and personal fees from AstraZeneca K.K. outside the submitted work. SO reports personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Ono Pharmaceutical, personal fees from AstraZeneca Pharmaceutical Co., personal fees from Boehringer Ingelheim Japan, Inc., personal fees from Taiho Pharmaceutical, and personal fees from MSD outside the submitted work. AO reports personal fees from Taiho Pharmaceutical, personal fees from Ono Pharmaceutical, personal fees from Chugai Pharmaceutical Co., Ltd., and personal fees from Novartis Pharma K.K. outside the submitted work. HM reports personal fees from AstraZeneca, personal fees from Ono Pharmaceutical, personal fees from Bristol-Myers Squibb Japan, personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Pfizer Inc., personal fees from Novartis Pharma K.K., personal fees from Boehringer Ingelheim, personal fees from Taiho Pharmaceutical, personal fees from Lilly Japan, and personal fees from Merck Sharp & Dohme outside the submitted work. EM reports personal fees from Ono Pharmaceutical, personal fees from AstraZeneca, and personal fees from Takeda Pharmaceutical Company outside the submitted work. HH reports personal fees from AstraZeneca, personal fees from Chugai Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Daiichi Sankyo, and personal fees from Brainlab outside the submitted work. YG has nothing to disclose. TT reports grants and personal fees from AstraZeneca K.K., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from MSD K.K., grants from Pfizer Japan Inc., personal fees from Boehringer Ingelheim Japan, INC, and personal fees from Roche Diagnostics K.K. outside the submitted work.Areas of circles show ILAs.